Anti-MUC1 aptamer: A potential opportunity for cancer treatment

被引:115
|
作者
Nabavinia, Maryam Sadat [1 ]
Gholoobi, Aida [2 ]
Charbgoo, Fahimeh [1 ,3 ]
Nabavinia, Mahboobeh [4 ]
Ramezani, Mohammad [1 ,5 ]
Abnous, Khalil [3 ,6 ]
机构
[1] Mashhad Univ Med Sci, Sch Pharm, Dept Pharmaceut Biotechnol, Mashhad, Iran
[2] Mashhad Univ Med Sci, Sch Med, Dept Modern Sci & Technol, Mashhad, Iran
[3] Mashhad Univ Med Sci, Pharmaceut Res Ctr, Mashhad, Iran
[4] Univ Illinois, Dept Bioengn, Chicago, IL USA
[5] Mashhad Univ Med Sci, Nanotechnol Res Ctr, Mashhad, Iran
[6] Mashhad Univ Med Sci, Sch Pharm, Dept Med Chem, Mashhad, Iran
关键词
antibody; aptamer; mucin 1 or MUC1; targeted therapy; EPITHELIAL OVARIAN-CANCER; BREAST-CANCER; MONOCLONAL-ANTIBODY; TARGETED DELIVERY; CHITOSAN NANOPARTICLES; EMERGING CLASS; DNA APTAMERS; IN-VITRO; MUC1; THERAPY;
D O I
10.1002/med.21462
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Mucin 1 (MUC1) is a protein usually found on the apical surface of most normal secretory epithelial cells. However, in most adenocarcinomas, MUC1 is overexpressed, so that it not only appears over the entire cell surface, but is also shed as MUC1 fragments into the blood stream. These phenomena pinpoint MUC1 as a potential target for the diagnosis and treatment of cancer; consequently, interest has increased in MUC1 as a molecular target for overcoming cancer therapy challenges. MUC1 currently ranks second among 75 antigen candidates for cancer vaccines, and different antibodies or aptamers against MUC1 protein are proving useful for tracing cancer cells in the emerging field of targeted delivery. The unique properties of MUC1 aptamers as novel targeting agents, and the revolutionary role that MUC1 now plays in cancer therapy, are the focus of this review. Recent advancements in MUC1-targeted cancer therapy are also assessed.
引用
收藏
页码:1518 / 1539
页数:22
相关论文
共 50 条
  • [41] Anti-MUC1 Antibodies and Ovarian Cancer Risk: Prospective Data from the Nurses' Health Studies
    Pinheiro, Simone P.
    Hankinson, Susan E.
    Tworoger, Shelley S.
    Rosner, Bernard A.
    McKolanis, John R.
    Finn, Olivera J.
    Cramer, Daniel W.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2010, 19 (06) : 1595 - 1601
  • [42] Upregulation of complement inhibitor expression on bladder cancer cells mediated by anti-MUC1 immune selection
    Varela, Juan C.
    Rapisardo, Michelle
    Sinha, Debajyoti
    Atkinson, Carl
    Tomlinson, Stephen
    MOLECULAR IMMUNOLOGY, 2007, 44 (1-3) : 253 - 253
  • [43] Myeloid derived suppressor cells (MDSC) and anti-MUC1 immunosurveillance in pre-malignancy and cancer
    Ma, Peiwen
    Beatty, Pamela
    McKolanis, John
    Schoen, Robert
    Brand, Randal
    Finn, Olivera J.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [44] Epitope mapping of anti-MUC1 mucin protein core monoclonal antibodies
    Petrakou, E
    Murray, A
    Price, MR
    TUMOR BIOLOGY, 1998, 19 : 21 - 29
  • [45] Nonspecific nuclear uptake of anti-MUC1 aptamers by dead cells: the role of cell viability monitoring in aptamer targeting of membrane-bound protein cancer biomarkers
    Flanagan, Shane Patrick
    Fogel, Ronen
    Edkins, Adrienne Lesley
    Ho, Lance St. John
    Limson, Janice
    ANALYTICAL METHODS, 2021, 13 (09) : 1191 - 1203
  • [46] Chitosan-gold nanocarrier for targeted delivery of anti MUC1: Opportunity for breast cancer treatment
    Dashtestani, F.
    Farahmand, L.
    Jalili, N.
    Majidzadeh-A, K.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S96 - S96
  • [47] CHARACTERIZATION OF A RECOMBINANT FV FRAGMENT OF ANTI-MUC1 ANTIBODY HMFG1
    DAVIES, GM
    BOSZE, S
    HUDECZ, F
    PRICE, MR
    TENDLER, SJB
    CANCER LETTERS, 1994, 82 (02) : 179 - 184
  • [48] Immunization with MUC1/X protein enhances cDNA immunization in generating Anti-MUC1 α/β junction antibodies that target cancer cells.
    Rubinstein, DB
    Ziv, R
    Carmeli, M
    Leitner, O
    Wreschner, DH
    CLINICAL CANCER RESEARCH, 2005, 11 (24) : 8980S - 8980S
  • [49] Anti-MUC1 Aptamer/Negatively Charged Amino Acid Dendrimer Conjugates for Targeted Delivery to Human Lung Adenocarcinoma A549 Cells
    Masuda, Marie
    Kawakami, Shigeru
    Wijagkanalan, Wassana
    Suga, Tadaharu
    Fuchigami, Yuki
    Yamashita, Fumiyoshi
    Hashida, Mitsuru
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2016, 39 (10) : 1734 - 1738
  • [50] Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma
    Treon, SP
    Maimonis, P
    Bua, D
    Young, G
    Raje, N
    Mollick, J
    Chauhan, D
    Tai, YT
    Hideshima, T
    Shima, Y
    Hilgers, J
    von Mensdorff-Pouilly, S
    Belch, AR
    Pilarski, LM
    Anderson, KC
    BLOOD, 2000, 96 (09) : 3147 - 3153